Guided Therapeutics (OTCMKTS:GTHP) Announces Quarterly Earnings Results

Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.

Guided Therapeutics Price Performance

GTHP opened at $0.11 on Tuesday. The company’s 50-day moving average is $0.18 and its 200 day moving average is $0.24. Guided Therapeutics has a fifty-two week low of $0.10 and a fifty-two week high of $0.54. The firm has a market capitalization of $10.80 million, a P/E ratio of -2.75 and a beta of 0.78.

Guided Therapeutics Company Profile

(Get Free Report)

Guided Therapeutics is a medical technology company focused on developing tools for the detection of cervical disease. Its principal product is the LuViva Advanced Cervical Scan, a non-invasive device designed to assess cervical tissue for signs associated with precancerous changes and cancer. LuViva uses optical technologies to examine tissue and provide information that can support cervical disease evaluation. The company’s work centers on offering an alternative to diagnostic approaches that rely on collecting and analyzing tissue samples.

Read More

Earnings History for Guided Therapeutics (OTCMKTS:GTHP)

Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.